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Copper, iron, and zinc are just three of the main biometals critical for correct functioning of
the central nervous system (CNS). They have diverse roles in many functional processes
including but not limited to enzyme catalysis, protein stabilization, and energy production.
The range of metal concentrations within the body is tightly regulated and when the
balance is perturbed, debilitating effects ensue. Homeostasis of brain biometals is mainly
controlled by various metal transporters and metal sequestering proteins. The biological
roles of biometals are vastly reviewed in the literature with a large focus on the connection
to neurological conditions associated with ageing. Biometals are also implicated in a
variety of debilitating inherited childhood disorders, some of which arise soon following
birth or as the child progresses into early adulthood. This review acts to highlight what we
know about biometals in childhood neurological disorders such as Wilson’s disease (WD),
Menkes disease (MD), neuronal ceroid lipofuscinoses (NCLs), and neurodegeneration with
brain iron accumulation (NBIA). Also discussed are some of the animal models available
to determine the pathological mechanisms in these childhood disorders, which we hope
will aid in our understanding of the role of biometals in disease and in attaining possible
therapeutics in the future.
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INTRODUCTION
The significance of biometals for the correct functioning of the
human brain has long been discovered. The importance of met-
als such as iron, zinc, and copper results from the numerous roles
that they have, such as stabilization of proteins and transcription
factors, acting as co-factors for metallochaperones for cellular
transport and their role in enzyme catalysis (Markossian and
Kurganov, 2003; Butterworth, 2010). Deviations of metal home-
ostasis have been linked to neurodegenerative disorders such as
Alzheimer’s disease (AD), Parkinson’s disease, Amyotrophic lat-
eral sclerosis, and Huntington’s disease (HD) (Dexter et al., 1993;
Deibel et al., 1996; Jomova et al., 2010; Skjorringe et al., 2012). A
risk factor in the development of many of these disorders appears
to be an increase in age. Although the pathological characteristics
of the disease are in most cases well-understood, the exact causes
are often unknown.
Neurodegeneration is not restricted to an ageing popula-
tion. Several debilitating neurodegenerative disorders affecting
children have been identified. These include neurodegeneration
with brain iron accumulation (NBIA), ATPase pathologies such
as Wilson’s/Menkes disease and neuronal ceroid lipofuscinoses
(NCLs). These disorders share several pathological features with
more common neurodegenerative diseases, including protein
aggregation and oxidative stress. Aberrant biometal homeostasis
has also been identified in children suffering from these diseases
(Table 1). What is not clear is whether the distinct changes in
metal levels cause neurodegeneration or occur as a result of the
neurodegeneration. In some cases, the pathology associated with
childhood disorders is clearly evident and often fatal at an early
age. Changes in metal levels have also been identified in children
with Autism spectrum disorder (ASD) which affects the behav-
ior of children more so than hinder them physically. Dissecting
the roles that biometals have in these disorders is fundamental for
finding potential therapeutics to reduce or inhibit neuropatho-
logical changes associated with altered metal homeostasis (Yasuda
et al., 2011).
Since biometal homeostasis plays a major role in neurodegen-
erative disease, the aim of this review is to highlight the effects that
metals have on the developing brain. Multiple childhood disor-
ders arise from defects in the concentrations of metals within the
body and brain but little is known about how these changes can be
corrected or prevented to avoid or ameliorate disease. While most
of the childhood disorders are inherited and disease progression
can occur not long after birth, it is critical to determine the molec-
ular disease characteristics and metal alterations within the brain
and other tissues for the development of therapeutic treatments
to provide these children with a chance at life.
WILSON’S DISEASE
Wilson’s disease (WD) is an autosomal recessive disease affecting
copper metabolism (Bearn and Kunkel, 1954). Copper is involved
in neurotransmitter synthesis, cellular respiration, scavenging of
toxic free-radicals, and has an important role in maintaining
homeostasis of other trace elements such as iron (Butterworth,
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Table 1 | Biometal alterations in childhood disorders.
Childhood
disorder
Associated Biometal
concentrationsgene(s)
Wilson’s disease ATP7B Copper ↑
Menkes disease ATP7A Copper ↓
Neuronal ceroid
lipofuscinoses
At least 10 genes Zinc, manganese, copper,
iron, cobalt, sodium ↑
Potassium, magnesium ↓
Neurodegenerative
disorders with iron
accumulation
At least 7 genes Iron ↑
2010). However, in abundance, copper is toxic and thus strict
regulation of levels is critical. Free copper ions are virtually non-
existent in human blood (Linder and Hazegh-Azam, 1996) and
are usually bound to a multitude of proteins and chaperones
for transport around the body. WD presents in patients typically
between the ages of 6–20 years, and has an estimated incidence of
1 in 30,000 (Reilly et al., 1993).
The defective gene involved in WD is ATPase Cu(2+)
transporting beta polypeptide (ATP7B), which encodes for a
membrane bound copper-transporting ATPase protein primarily
located within the liver cells, as part of the trans golgi network
(Cox and Moore, 2002). To date, approximately 300 mutations
within ATP7B have been associated with WD (Merle et al.,
2010). Normal copper metabolism involves the transfer of cop-
per molecules to ceruloplasmin for transport into the plasma so
it can circulate to other tissues or when in excess, to the bile for
excretion (Terada et al., 1998, 1999). ATP7B is involved in trans-
porting the copper molecules to ceruloplasmin. When ATP7B is
non-functional, copper accumulates to toxic levels and severely
damages the liver. The liver therefore releases copper directly
into the bloodstream where copper continues to cause damage
to other tissues, in particular the CNS. In the brain, accumula-
tion of copper is most evident in the basal ganglia, the region
which co-ordinates movement (DeLong et al., 1984), makingWD
primarily a movement disorder. This neuropathology caused by
the build up of copper leads to patients suffering tremors of the
arms or hands, unpredictable movement, difficulty with speak-
ing, swallowing, and walking as well as confusion, dementia,
and various psychological problems (Rosencrantz and Schilsky,
2011). Some cognitive deficits have also been noted (Middleton
and Strick, 2000), and could arise due to disruptions of projec-
tions of the basal ganglia to the prefrontal cortex (Bolam et al.,
2000). Gliosis is also observed in the brains of patients suffering
from WD (Anzil et al., 1974). The mechanism for neurologi-
cal damage caused by excess copper is still not fully understood.
However, it is known that copper is involved in the produc-
tion toxic free radicals (Samuele et al., 2005), and excess copper
has been shown to inhibit Inhibitor of apoptosis proteins (IAPs)
caused by toxic deposits of intracellular copper (Mufti et al.,
2006).
WD is a progressive disorder and was ultimately a fatal dis-
ease until the discovery of the first treatment in 1951 (Denny-
Brown and Porter, 1951). With the copper-chelating agent,
dimercaptopropanol, the disease is now treatable (Denny-Brown
and Porter, 1951). The most common treatment to date is the use
of zinc salts, which block enteral copper absorption in the stom-
ach. Various drugs are currently available for WD and ongoing
compliance with treatment is necessary.
ANIMAL MODELS OF WD
The Long Evans Cinnamon (LEC) rat is one model used for
in vivo studies of WD. Since showing symptoms of liver failure in
1987 (Yoshida et al., 1987), the rats were first used as a model for
liver cancer and hepatitis. Upon further characterization, accu-
mulation of hepatic copper and decreased ceruloplasmin activity
were found. Years later when the gene responsible for WD was
discovered, the rat homolog atp7bwas found to be mutated in the
LEC rats, with a significant deletion at the 3′ end of the gene (Wu
et al., 1994). Although there are similarities in liver pathogenesis
between the LEC rat and humans, this rodent model shows min-
imal evidence of neuropathology (Terada and Sugiyama, 1999).
In contrast to the LEC rat model, ATP7B knockout mice exhibit
both neuro- and liver pathology. In these mice, copper levels are
dramatically low at birth with a gradual increase by 2 months
of age, where hepatic copper levels are approximately 50 times
higher compared to wild-type controls (Buiakova et al., 1999).
Another interesting model for WD is the toxic milk mouse, which
also has an autosomal recessive inheritance (Theophilos et al.,
1996). Female mice with the tx milk mutation produce copper-
deficient milk, which is fatal to their pups. The tx mice have a
single nucleotide change in the ATP7B gene, and studies have
shown this to cause changes in the ATP7B localization in the
mammary gland, therefore leading to impaired copper trans-
port and little to no copper given to the pups. The tx mothers
retain this copper in the liver (Rauch, 1983; Michalczyk et al.,
2000).
Both the LEC rat and tx milk mouse models arose from
spontaneous mutations. There is only one genetically engineered
mouse model for WD, the ATP7b−/− mouse, which was gener-
ated by Buiakova et al. (1999). ATP7b−/− mice are born copper-
deficient and display neurological symptoms such as tremors
and abnormal locomotor behavior. If nursed by a homozygous
ATP7b−/−mother, the pups will die at around 2 weeks of age.
However, if nursed by a heterozygous mother, copper concentra-
tions begin to rise to toxic levels in the liver by the age of 6 weeks,
irrespective of initial birth concentration. Similar to human dis-
ease, these mice accumulate copper in the liver due to impaired
export of copper into the bile, making these mice an invaluable
model for the study of WD (Lutsenko, 2008).
MENKES DISEASE
Menkes disease (MD) is an inherited disease related to copper
metabolism, but in contrast to WD, it is characterized by a sig-
nificant reduction in normal copper levels in the blood, liver,
and brain (Danks et al., 1973). Disease progression is also more
rapid than in WD (de Bie et al., 2007). The reduction of cop-
per is due to decreased absorption of copper from the intestine
and therefore reduced transfer to copper-requiring proteins and
enzymes (Danks, 1988). Symptoms present within the first year
of life, generally within 3 months of birth and without treatment,
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death is likely before the third year of life. MD is a rare childhood
disease with an estimated worldwide incidence of 1 in 300,000
(Tonnesen et al., 1991), but can be higher in certain countries
such as Australia (1 in 50,000 to 1 in 100,000) (Tumer andMoller,
2010).
MD has an X-linked mode of inheritance and is more preva-
lent in males than females (Kodama and Murata, 1999). At birth,
babies appear normal, although premature labor has been docu-
mented (Uriu-Adams et al., 2010). An early sign in a baby with
MD is the presence of sparse and abnormal hair, which looks
fragile and twisted and appears to have a “kink” in it (Kaler,
2011). MD is thus also referred to as “Kinky Hair Syndrome.”
The baby begins to exhibit normal cognitive behavior with smil-
ing and normal childhood dialogue; however, these behaviors do
not progress further. Babies do not exhibit increases in muscle
tone and over time generally become weaker and spasticity of
the limbs is observed. Toward the end of the babies’ short life,
they succumb to blindness and respiratory failure and premature
death is often due to infection or the extreme neuronal degen-
eration observed. A less-severe form of MD is called occipital
horn syndrome (OHS) which is also an X-linked recessive inher-
ited disorder with mutations in ATP7A. These patients exhibit
fewer neurologic abnormalities and have a longer lifespan (Tumer
and Moller, 2010). Connective tissue abnormalities tend to be
the focus of this disorder with calcification of the occipital bulb,
leading to horn-like structures at the base of the brain.
This detrimental disease is caused by a mutation in the gene
encoding the Copper transporting ATPase-1 (ATP7A) protein
(Fatemi and Sarkar, 2002), which is also a “P-type” ATPase
protein similar to ATP7B. To date, there are over 200 known
mutations scattered throughout the gene (His and Cox, 2004).
Although both ATP7A and ATP7B are involved in the transport
of copper to secreted enzymes and metalloproteins, ATP7A is also
involved in the absorption of intestinal copper and can trans-
port copper to all cell types and vital structural enzymes (Barry
et al., 2011). ATP7B is predominantly involved in the exit of cop-
per from hepatocytes. These differences in protein function are
demonstrated by the fact that MD patients exhibit a variable
range of symptoms throughout the body as opposed to mainly
liver damage seen in patients with WD. The neurological dam-
age caused by mutant ATP7A is due to the decreased activity
of the copper-dependent enzymes. Decreased cytochrome c oxi-
dase leads to a reduction in ATP production by the mitochondria
and causes apoptotic cell death (Borm et al., 2004). Dopamine-
β-hydroxylase is necessary for neurotransmitter synthesis and its
activity is decreased in response to low copper levels (Kaler et al.,
1995). Superoxide dismutase 1 (SOD1) is a free-radical scavenger
the activity of which has been linked to several neurodegenera-
tive disorders, particularly ALS. Copper is a co-factor imperative
for SOD1 activity. Levels of SOD1 are decreased in MD patients,
contributing to lower protection against toxic oxidative species
within the brain (Kaler, 1994). Collectively, the reduced activity
of copper-dependent enzymes is thought to be responsible for the
observed neurological damage in MD.
The cellular location of ATP7A is sensitive to the concentra-
tion of copper; when copper levels are low ATP7A remains on the
membrane of the Golgi but when levels are increased, ATP7A is
located to the plasma membrane where it can “pump” copper to
other proteins and cuproenzymes (Hasan et al., 2012). In MD,
where copper levels are low, it is essentially located to the Golgi
and there is a deficiency of copper transport to essential enzymes,
and other tissues.
The therapeutic benefit of injection of copper histidine as a
copper replacement to humans has provided mixed results and is
dependent on the mutation within the ATP7A gene (Kaler et al.,
1995; Christodoulou et al., 1998). Some studies have shown that
early administration of copper to babies can prevent the observed
neurological decline but this is likely to be in patients with muta-
tions in ATP7A that still allow for some transfer of copper to
copper-requiring enzymes, but not severe mutations affecting
initial absorption from the intestine (Tumer et al., 1996).
ANIMAL MODELS OF MD
Spontaneous mutations in the mouse homolog of ATP7A, atp7a,
have been used for modeling defective ATP7A in humans (Kuo
et al., 1997). These mice are called mottled mice and different
mutations in the atp7a gene cause different neurological and con-
nective tissue anomalies. The two mottled mice mutations mot-
tled brindled (Mobr) and mottled macular (Moml) show severe
reductions in copper within the liver (Hunt and Clarke, 1983),
and die within 1–3 weeks of birth (Lenartowicz et al., 2012). This
premature death can be prevented with injected copper within the
first week of birth, as well as transgenic over expression of atp7a
(Danks, 1986).
NEURONAL CEROID LIPOFUSCINOSIS
The NCLs are a group of fatal autosomally-inherited neurode-
generative diseases occurring in childhood. The NCLs are also
classified as lysosomal storage disorders since one of the main
pathological characteristics is the accumulation of autofluores-
cent granules which contain lipids and proteins (lipopigments)
in the lysosomes. Currently at least ten forms of NCLs have
been described. Each form is distinguished by different defec-
tive genes (CLNs) and the age of onset (Cooper, 2003; Mitchison
et al., 2004). Collectively, it is the most common neurodegen-
erative disorder of childhood with an estimated incidence of
up to 1:12,500 (Rider and Rider, 1999). Although mutations in
different genes cause different forms of the disease, all NCLs
share common clinical symptoms; progressive loss of vision lead-
ing to blindness, motor and mental retardation, seizures, and
finally premature death (Siintola et al., 2006). The exact func-
tion of these genes is still unknown (Tyynela et al., 2004).
These genes encode soluble proteins and membrane-bound pro-
teins, for example, CLN6 is a transmembrane protein which
is localized to the endoplasmic reticulum (Heine et al., 2004).
Children with defective CLN6 present with symptoms at the
age of 3–5 years and tend to only live until 8–12 years of age.
Currently there is no cure for any form of NCL (Sharp et al.,
2003).
In NCLs, early reports have described some changes to metal
levels, including iron and zinc, in blood cells of patients with NCL
(Johansson et al., 1990). In a larger study of NCL patients, no
association between “loosely bound” iron or copper levels in cere-
brospinal fluid could be found (Heiskala et al., 1988). There is
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some evidence that altered metal homeostasis may also occur in
other NCL models. A recent study reported changes in expres-
sion of the metal transporter, ZnT6, in both CLN3 and CLN6
mouse cerebellar neuron precursor cell lines (Cao et al., 2011).
Furthermore, reduction in expression of the gene causing CLN7
NCL disease was observed in the brains of mice fed a high-iron
diet (Johnstone and Milward, 2010), suggestive of a heightened
sensitivity of NCL brains to fluxes in metal concentrations.
Recently, a link between brain biometal homeostasis andCLN6
disease was discovered. Sheep harboring a natural mutation in the
CLN6 gene show significant increases in manganese and more
so, zinc levels in all brain regions except the cerebellum and
brain stem (Kanninen et al., 2013). In the CLN6 sheep model,
the accumulation of biometals was evident at the symptomatic
age of 12–14 months. Early studies on the metal contents of
lipopigments from CLN6 sheep revealed no obvious association
between metal contents and disease progression (Palmer et al.,
1988). Metal contents were variable between lipopigments from
different tissues in line with the normal role of lysosomes as
storage depots for metals, indicating the lysosomal origin of the
lipopigments. Changes in the metal contents of retina and retinal
pigment epithelial cells of CLN6 sheep have been reported, and
an association with lipopigment accumulation and altered man-
ganese levels with increasing photoreceptor cell loss suggested
(Jolly et al., 1989).
ANIMAL MODELS OF NCLs
To understand the pathogenesis of NCLs, gene-specific mutant
mice have been engineered which contain mutations in Cln1,
Cln2, Cln3, Cln5, Cln7, and Cln10 genes (Cooper et al., 2006).
Naturally occurring mutations in Cln6 and Cln8 have also been
identified (Lonka et al., 2000; Gao et al., 2002). Many of these
mousemodels share phenotypic features in commonwith human
patients such as neurological and motor deficits, seizures and
neuronal loss, and as such, are valuable tools to study dis-
ease mechanisms and potential therapeutic approaches. Like
the human form, the mouse models display variance in tim-
ing and sequence of events toward disease progression, high-
lighting the genetic differences between the NCLs (Cooper
et al., 2006). As the function of the majority of these genes
is still unknown, using these animal models will prove invalu-
able in elucidating the function and mechanism behind NCL
pathologies. The naturally occurring mutation in the CLN6
gene of sheep mentioned above share a similar disease pro-
gression and phenotypic features similar to that of the human
CLN6 NCL form (Jolly et al., 1989; Kay et al., 2011), mak-
ing them an excellent model of NCL disease due to their
complex CNS. However, with large animal models it may be
challenging to obtain sufficient numbers of animals for assess-
ment due to difficulties in breeding and housing such large
animals.
NEURODEGENERATIVE DISORDERS WITH BRAIN IRON
ACCUMULATION
As with copper and zinc mentioned above, levels of iron within
the brain need to be tightly regulated. Iron homeostasis is
regulated by proteins involved in absorption, transport, influx,
and storage in tissues (Zhang and Enns, 2009). Increases in brain
iron levels are typically associated with ageing and is highly preva-
lent in AD and HD. Neurodegenerative disorders with brain
iron accumulation (NBIA) refers to a wide group of disorders
affecting children, with similar outcomes: neurodegeneration and
the accumulation of iron. The disease is caused by mutations
in seven genes (Ke and Ming Qian, 2003). At birth, brain iron
is not present, but levels rapidly increase until 20 years of age
with an uneven distribution over time (Zorzi et al., 2012). The
most recognized gene defects are mutations in pantothenate
kinase (PANK2), which is an enzyme located within the mito-
chondria and regulates the formation of Coenzyme A, which is
essential for deriving cellular energy via the tricarboxylic acid
cycle (Leoni et al., 2012). PANK2 phosphorylates pantothen-
ate and requires N-pantothenoyl-cysteine and pantetheine. The
exact mechanism how mutations in PANK2 lead to iron accu-
mulation is not fully understood, but one hypothesis is that if
cysteine cannot be utilized within the cell by PANK2, it accu-
mulates over time. Cysteine can bind iron, and over time this
may explain the observed accumulation of iron (Gregory and
Hayflick, 2005). Although the mutation in PANK2 directly does
not cause neurodegeneration, it is the increased iron which con-
tributes to the production of toxic and tissue-damaging reactive
oxygen species (Ke and Ming Qian, 2003). Increases in iron have
also been linked to several neurological disorders such as AD
and PD (Batista-Nascimento et al., 2012). There are over 100
mutations in this gene and PANK2 disorders account for over
half of all NBIA cases (Gregory and Hayflick, 2005). PANK2-
specific NBIA, referred to as pantothenate kinase-associated neu-
rodegeneration (PKAN) was formally called Hallervorden–Spatz
syndrome before the name was changed to divert any associ-
ation with the unethical euthanization of mentally ill patients
during World War II by Dr. Hallervorden (Dooling et al., 1974).
PKAN disease is autosomally inherited and presents in child-
hood as either the classical, early onset or atypical, late onset
form (Hayflick et al., 2003). The extent of iron accumula-
tion can be easily visualized and quantified using magnetic
resonance imaging (MRI). The pattern exhibited by MRI-T2
weighted images shows the increased iron as “darkened spots”
and provides a novel “eye of the tiger” image, making MRI an
important diagnostic tool for NBIA (Schenck and Zimmerman,
2004).
The symptoms of classical PKAN disease become apparent
within the first 10 years of life, with symptoms usually start-
ing between 3 and 4 years of age. Affected children begin to
have difficulty with walking and other movements, which is
attributed to the build up of iron in the basal ganglia (Gregory
and Hayflick, 2005), a region of the brain highly important in
movement. Rigidity, spasticity, and speech difficulties soon fol-
low (Dooling et al., 1974). Children become wheelchair bound
within only a few years of diagnosis. Atypical PKAN disease
begins later in life, with an average age of onset of 13–14
years and disease progression unfolds slowly over many years
(Chan et al., 2008). Patients present firstly with behavioral prob-
lems such as depression and personality changes with move-
ment and speech impediments following later. The symptoms
of atypical PKAN can be highly variable from case to case.
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Treatment for NBIA had been aimed at symptoms rather than
the genetic defect causing the iron build up and severe neurode-
generation. Drugs aimed at reducing abnormal movement are
widely prescribed, but to date, there is no preventative for NBIA
disorders. Recently, reducing the accumulation of iron has been
the target for treatment using iron-chelators, however this is met
with varying efficacy (McNeill and Chinnery, 2011). Deferiprone
is an iron chelator which acts to redistribute iron within the brain,
by donating built-up iron to transferrin for transport elsewhere
(Brittenham, 1992). The promising feature of this drug is the abil-
ity to cross the blood-brain barrier, necessary for targeting the
build up of iron in CNS. However, no conclusive results can be
drawn from these clinical studies due to the small number of
patients trialed (Forni et al., 2008; Zorzi et al., 2011).
ANIMAL MODELS OF NBIA
Unlike the other childhood disorders discussed in this review,
PKAN-NBIA does not have a suitable murine model of disease.
A PANK2 knockout mouse was generated which showed retinal
degeneration and growth retardation, but no defects on move-
ment and gait were evident (Kuo et al., 2005; Brunetti et al.,
2012). However, Drosophila melanogaster have been a powerful
tool for understanding the biochemical basis of PANK2 muta-
tions. Mutations in the homolog of PANK, fumble (fbl) exhibited
a shortened lifespan, progressive locomotion defect, and degen-
erations in both central nervous system and retina (Gregory and
Hayflick, 2005). Interestingly, mutations in PANK2 in both the
Drosophila and mouse led to male sterility (Wu et al., 2009).
CONCLUSIONS
The importance of metals in neurological disease has been out-
lined in numerous reviews over many decades, however, the exact
mechanisms leading to aberrant metal homeostasis and why this
is so detrimental to the brain remain poorly understood. While
the brain is still developing during childhood, it is highly sus-
ceptible to slight changes in metal levels as outlined above with
discussion of various childhood neurodegenerative disorders.
Although certain therapeutics exist for some of these disorders,
they mainly target disease symptoms and prolong the disease,
rather than being preventative. It is the work forthcoming from
in vitro, animal and clinical studies, which aim to add insight into
the role ofmetal changes and consequences so potential therapeu-
tics can be tested and hopefully one day applied to prevent disease
progression.
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